INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2006

Adding L-arginine to standard postinfarction therapy did not improve vascular stiffness or ejection fraction and may be associated with higher mortality.

A randomized controlled trial evaluated adding L-arginine (goal dose 3 g 3 times daily) or placebo for 6 months to standard therapy in 153 patients following a first ST-segment elevation myocardial infarction. There was no significant change from baseline to 6 months in vascular stiffness measurements or left ventricular ejection fraction in either group, including participants aged 60 or older. However, 6 participants (8.6%) in the L-arginine group died during the study compared with none in the placebo group (P = .01). Due to these safety concerns, enrollment was closed early.

Study type
Randomized, double-blind, placebo-controlled trial
Who was studied
153 patients following a first ST-segment elevation myocardial infarction (77 aged 60 or older)
What was measured
Change in ejection fraction and vascular stiffness at 6 months; clinical events

THE PAPER

L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.

Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. JAMA, 2006.

PubMed 16391217 ↗DOI 10.1001/jama.295.1.58 ↗

Heart & arteries

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.